Amgen Inc. (NASDAQ:AMGN – Free Report) – Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th.

A number of other research firms have also recently issued reports on AMGN. Piper Sandler cut their target price on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

CRISPR Therapeutics is a leader in gene editing and could make important breakthroughs. Amgen has a strong lineup of products, a deep pipeline, and a strong dividend program. Regeneron should ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other stocks that Jim Cramer discusses that are leading the Dow higher in 2025. On Thursday ...

Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...

That's why it might be worth it to consider this stock at current levels. Amgen's shares fell late last year after it released phase 2 data for its weight loss candidate, MariTide. Though the ...